Cytokinetics, Incorporated · NASDAQ:CYTK

Malik Fady Ibraham sold 4,500 Cytokinetics, Incorporated shares (Form 4)

Traded Apr 7, 2026 · Filed Apr 8, 2026

On Apr 7, 2026, Malik Fady Ibraham (EVP Research & Development) sold 4,500 Cytokinetics, Incorporated shares at an average US$65.11 for US$293K under a trading plan, leaving 153,902 shares. Filed Apr 8, 2026 (Form 4).

Sold
4,500 shares
Price
US$65.11 average (US$64.75 to US$65.21)
Value
US$293K
Holding after
153,902 shares
Trading plan
Yes (Made under a plan set in advance)
Role
EVP Research & Development

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 7, 2026Common StockOption exercise3,500US$7.80157,402Direct
Apr 7, 2026Common StockSale3,500US$65.21153,902Direct
Apr 7, 2026Common StockOption exercise1,000US$10.60154,902Direct
Apr 7, 2026Common StockSale1,000US$64.75153,902Direct

Source

View original at SEC

Related